PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Price Stock Quantity  
USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD184352 (CI-1040) Chemical Structure

PD184352 (CI-1040) Chemical Structure
Molecular Weight: 478.67

Validation & Quality Control

Product Use Citation(42)

Customer Product Validation(12)

Quality Control & MSDS

Related Compound Libraries

PD184352 (CI-1040) is available in the following compound libraries:

MEK Inhibitors with Unique Features

Product Information

  • Compare MEK Inhibitors
    Compare MEK Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Targets MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
IC50 17 nM 17 nM
In vitro CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H9NHi5UJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELVSIpKSzVyPUCuNFIzPzZizszNMmTaV2FPT0WU
CHP-212NIDLTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLDXVhKSzVyPUCuNFI5QDVizszNMnHpV2FPT0WU
EoL-1-cellMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TESmlEPTB;MD6wOFE2OiEQvF2=NVrxUW1QW0GQR1XS
DU-4475MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2m1V2lEPTB;MD6wO|U6QSEQvF2=MXjTRW5ITVJ?
MMAC-SFM12wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjlWWt7UUN3ME2wMlExQTd2IN88US=>MXXTRW5ITVJ?
AGSM{jhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHyTWM2OD1yLkGxO|E{KM7:TR?=MmnaV2FPT0WU
M14NEX1TmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlK3TWM2OD1yLkG1OFY5KM7:TR?=MVnTRW5ITVJ?
CP50-MEL-BMoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXRW|lKSzVyPUCuNVczPTRizszNNGLh[HVUSU6JRWK=
C32NFvWepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkT2TWM2OD1yLkG5NFczKM7:TR?=MkDGV2FPT0WU
KMOE-2MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLQfJhKSzVyPUCuNVk4QTVizszNM{DqN3NCVkeHUh?=
A101DNEnIdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVT5eoczUUN3ME2wMlIyPCEQvF2=MlzZV2FPT0WU
KM12NYrLdXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXOenFKSzVyPUCuNlQxPTdizszNNYLGeo1JW0GQR1XS
HSC-4MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfCdJREUUN3ME2wMlI1Ozl3IN88US=>MULTRW5ITVJ?
NOMO-1MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3LTWM2OD1yLkK1O|QzKM7:TR?=MXrTRW5ITVJ?
MZ7-melMljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHIdZNKSzVyPUCuNlY{PCEQvF2=NF;rTG5USU6JRWK=
ACNNV3qeJRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfhSZNVUUN3ME2wMlI3PzN5IN88US=>NETWSmVUSU6JRWK=
MEL-HONHfsTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjCTWM2OD1yLkK3OlUzKM7:TR?=MYLTRW5ITVJ?
BHT-101MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4GwR2lEPTB;MD6yPFYxPiEQvF2=MWrTRW5ITVJ?
SK-MEL-28NYXTV2FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\WWo9KSzVyPUCuN|A1ODlizszNNYXJcXU5W0GQR1XS
KG-1M4TNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rvS2lEPTB;MD6zNFY3QCEQvF2=NFnNPXFUSU6JRWK=
COLO-679NF6weItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{S4e2lEPTB;MD6zNlczKM7:TR?=NIfVUHNUSU6JRWK=
SK-MEL-24NILnWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIW2[W5KSzVyPUCuN|I5OTNizszNMY\TRW5ITVJ?
G-361M4DqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjtfYdZUUN3ME2wMlM3Pzl3IN88US=>MYrTRW5ITVJ?
KY821Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\TTWM2OD1yLkO3PVEh|ryPM1PSVnNCVkeHUh?=
KASUMI-1M2jtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPNZYN2UUN3ME2wMlM6QSEQvF2=M2X6ZXNCVkeHUh?=
HL-60MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonlTWM2OD1yLkSxNVA4KM7:TR?=MmS4V2FPT0WU
K5NEPZNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTBwNEOxNVch|ryPNF3GPVdUSU6JRWK=
KU812NUDSV3MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;WdYY6UUN3ME2wMlQ2Ojl7IN88US=>MnrKV2FPT0WU
SH-4Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTBwNE[yOVYh|ryPMnfxV2FPT0WU
HTC-C3MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTBwNE[1N|Eh|ryPNXnC[YhlW0GQR1XS
CP66-MELMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLlcHdbUUN3ME2wMlQ5QDB7IN88US=>M1nCd3NCVkeHUh?=
WM-115NYmxO3Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTBwNEmyOVch|ryPNF\MTJNUSU6JRWK=
A2780MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILycWZKSzVyPUCuOFk5OjNizszNMXfTRW5ITVJ?
P12-ICHIKAWANHPBbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTvZlkzUUN3ME2wMlYyOjJzIN88US=>Mon5V2FPT0WU
HMV-IIMl\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmT1TWM2OD1yLk[0OFY2KM7:TR?=MUPTRW5ITVJ?
HT-144MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfhTopKSzVyPUCuOlQ3PTdizszNNFH2RmJUSU6JRWK=
LB2518-MELNIXDT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnWwTWM2OD1yLkexOlMzKM7:TR?=NUXxTlNKW0GQR1XS
NCI-SNU-1NWCx[|J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXKbWhOUUN3ME2wMlc2PDN|IN88US=>Mk\sV2FPT0WU
C2BBe1NEDweItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWqybXRwUUN3ME2wMlgyODJ|IN88US=>M3m1fHNCVkeHUh?=
PSN1NU\UNVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\nOYJKSzVyPUCuPVYyQTZizszNM2H3TXNCVkeHUh?=
UACC-257NF3DTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7kTWM2OD1yLkm2OFc{KM7:TR?=NHfvOZNUSU6JRWK=
RVH-421NIfOeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnlTYRCUUN3ME2wMlk4OThizszNM2PnOHNCVkeHUh?=
GP5dNH\X[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLUTIdKSzVyPUCuPVg{ODhizszNNFTzOYVUSU6JRWK=
TYK-nuM1vySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFwMEOxO|Ih|ryPMYnTRW5ITVJ?
SK-N-ASM4fjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rEcWlEPTB;MT6wO|k1PyEQvF2=NF\XZmNUSU6JRWK=
SW620NF;Ob4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTFwMUO1N|Qh|ryPMn\LV2FPT0WU
HuP-T4NYjERZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XpVmlEPTB;MT6xPFM2QSEQvF2=NIe1c45USU6JRWK=
A549Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFm4R|dKSzVyPUGuNVk2PzZizszNMWfTRW5ITVJ?
MewoMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHlVoFKSzVyPUGuNlAzPzZizszNNIixVHpUSU6JRWK=
ONS-76MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\H[mdqUUN3ME2xMlIzODR7IN88US=>MWTTRW5ITVJ?
SK-MEL-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrxbVJKSzVyPUGuNlM1OTlizszNMmC0V2FPT0WU
RCM-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{f1bmlEPTB;MT6yOFA1PyEQvF2=MoDsV2FPT0WU
H-EMC-SSMoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLxZ49{UUN3ME2xMlI6PjB6IN88US=>NGXic|hUSU6JRWK=
NCI-H2291MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHaTI9KSzVyPUGuN|I2OzZizszNM1LI[nNCVkeHUh?=
SW1463MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mon5TWM2OD1zLkOzO|IyKM7:TR?=M4rrTHNCVkeHUh?=
LS-411NNWjUemN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\T[HVKSzVyPUGuOFA2OTdizszNM1zYW3NCVkeHUh?=
BV-173NVjmT2o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXThPGVPUUN3ME2xMlQ1ODF3IN88US=>NV3mXFhJW0GQR1XS
LS-513NWXOV4NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXH4S2MyUUN3ME2xMlQ2OTl{IN88US=>NGXEOo5USU6JRWK=
LoVoMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDzPIhKSzVyPUGuOFY{QTlizszNNUO3TVJYW0GQR1XS
HO-1-N-1M122emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXsTWM2OD1zLkWxOlM1KM7:TR?=M1TMOXNCVkeHUh?=
ML-2M4PBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4X4OGlEPTB;MT61Nlg3QCEQvF2=NXvh[ZpTW0GQR1XS
NCI-H1437MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M360RmlEPTB;MT61OVI4PSEQvF2=M2qyOHNCVkeHUh?=
SW1116M1jmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTFwNU[zPVgh|ryPM125eHNCVkeHUh?=
A4-FukMofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2j3fmlEPTB;MT61O|A1PSEQvF2=NWPPNYhbW0GQR1XS
HD-MY-ZMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jMS2lEPTB;MT61O|M4PiEQvF2=NGDTenBUSU6JRWK=
SK-MEL-2MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfsNWhKSzVyPUGuOVc1PTlizszNNVzld|V{W0GQR1XS
RT-112MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3rTWM2OD1zLkW4PVUzKM7:TR?=NHK2eI5USU6JRWK=
COLO-829MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3meWxpUUN3ME2xMlYzOjN{IN88US=>MYjTRW5ITVJ?
OVCAR-5Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHr1V|RKSzVyPUGuO|c3QDdizszNNIj5cVZUSU6JRWK=
NB69MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13zV2lEPTB;MT63PFQ3QSEQvF2=MlLsV2FPT0WU
NCI-H292MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILQepFKSzVyPUGuPFY3QTlizszNNXPuPW5jW0GQR1XS
LOXIMVINYe3dm17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHvSokzUUN3ME2xMlg6PDJ5IN88US=>MnzxV2FPT0WU
BPH-1NUjzfmFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTFwOEm1PVEh|ryPNEizS29USU6JRWK=
A375MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTFwOEm3NVQh|ryPM1\QR3NCVkeHUh?=
LCLC-97TM1NXHkepJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{WxfGlEPTB;MT65NlI2PiEQvF2=NUfoZ413W0GQR1XS
RXF393M{OyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLVem1KSzVyPUGuPVc5QDdizszNNGPWe3lUSU6JRWK=
HCC70MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTJwMEK0NlYh|ryPMmnmV2FPT0WU
EM-2NUntfGF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnZNJg6UUN3ME2yMlA4OTl6IN88US=>NGSzT3VUSU6JRWK=
MZ2-MELMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vHfmlEPTB;Mj6xNVEzPyEQvF2=M{nwdHNCVkeHUh?=
HNNHfHdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mom5TWM2OD1{LkG2Nlc5KM7:TR?=NXnGZVlkW0GQR1XS
A2058MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVro[JUzUUN3ME2yMlE6Ojd7IN88US=>M{LpR3NCVkeHUh?=
NB7NEPjTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLOZXR4UUN3ME2yMlM1ODh4IN88US=>M3[3fHNCVkeHUh?=
DOKMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPnTWM2OD1{LkO1O|c{KM7:TR?=MX3TRW5ITVJ?
CAL-27MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTJwM{myN|Yh|ryPNEi3OnlUSU6JRWK=
BB65-RCCNUD1UZlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULuN4JsUUN3ME2yMlQxPjd2IN88US=>Ml:1V2FPT0WU
RDMlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIW1U|dKSzVyPUKuOFQ4OjNizszNNETufY1USU6JRWK=
KNS-62NVLQZWNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PMPWlEPTB;Mj61NVE3PCEQvF2=NHnYTYxUSU6JRWK=
EW-13NWXvPVNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFu1fGpKSzVyPUKuOVY{OzlizszNMYPTRW5ITVJ?
DBNEHyfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX:1R4hjUUN3ME2yMlU5Pzh6IN88US=>MkOyV2FPT0WU
HCC2218M1TMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TuO2lEPTB;Mj62OFc4QCEQvF2=NXi2fppqW0GQR1XS
L-363NV61WYE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;4[GpKSzVyPUKuO|Q{PyEQvF2=NEjkdldUSU6JRWK=
CHL-1MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\YSHdtUUN3ME2yMlgxPzh3IN88US=>MUTTRW5ITVJ?
BFTC-905Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzOXohKSzVyPUKuPFI2OyEQvF2=NFHIeGpUSU6JRWK=
HCE-TNIHhVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\jWHZ3UUN3ME2yMlg{OjZ2IN88US=>NGnWdXlUSU6JRWK=
COLO-792MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPiUYVKSzVyPUKuPFQxOjdizszNMWfTRW5ITVJ?
LB2241-RCCM{ju[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvZTWM2OD1{Lki1PFk{KM7:TR?=MULTRW5ITVJ?
CAL-39MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnMTWM2OD1{Lki5PVk6KM7:TR?=MVHTRW5ITVJ?
T-24MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\DTWM2OD1{LkmxNVEzKM7:TR?=Mo\5V2FPT0WU
NCI-H727M4DyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUewXndyUUN3ME2yMlkyPzl4IN88US=>M2i3S3NCVkeHUh?=
Ca9-22NEnsRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XtSmlEPTB;Mj65O|I2PSEQvF2=M123d3NCVkeHUh?=
MIA-PaCa-2NITUVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vJ[WlEPTB;Mz6wNFc5OSEQvF2=NV:zWGpMW0GQR1XS
HT-1080M{XDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInDOG5KSzVyPUOuNFE6QTdizszNM2H6cXNCVkeHUh?=
D-423MGNXrCclBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHqyZlZKSzVyPUOuNFc4PTNizszNM3T5WXNCVkeHUh?=
LAMA-84M1\kfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPvRnZKSzVyPUOuNVM2QCEQvF2=NH\VRXVUSU6JRWK=
SW780M{TlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1qwTWlEPTB;Mz6xOFIzQSEQvF2=MVHTRW5ITVJ?
KU-19-19MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTNwMUewN|Qh|ryPMnGxV2FPT0WU
COLO-741NIjSdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLSSoJCUUN3ME2zMlE5Pjd|IN88US=>M2nlWHNCVkeHUh?=
HSC-3M4K3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4npNmlEPTB;Mz6yN|E2OSEQvF2=MmnaV2FPT0WU
SN12CM1jRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrEeG1KSzVyPUOuNlQ4ODFizszNMVPTRW5ITVJ?
786-0M3OweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITuZWJKSzVyPUOuNlczPDNizszNNYP6W4tVW0GQR1XS
GAKMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\sRYFMUUN3ME2zMlMzPTZzIN88US=>NV\PeFVoW0GQR1XS
PANC-03-27MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml20TWM2OD1|LkO1NFQ2KM7:TR?=NXnFNXc2W0GQR1XS
CTB-1NYDoSVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHSTWM2OD1|LkS3NFQ4KM7:TR?=MXXTRW5ITVJ?
A427NITaTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jrbmlEPTB;Mz61PVU2PiEQvF2=NUPFcpY3W0GQR1XS
EGI-1NHzqd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moe1TWM2OD1|Lk[wOVg{KM7:TR?=MnvTV2FPT0WU
U-2-OSNETw[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTNwNkeyOVYh|ryPM3e2O3NCVkeHUh?=
NCI-SNU-5M{PRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;UUWlEPTB;Mz62O|c{KM7:TR?=NETiW29USU6JRWK=
SK-LU-1M1G5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTNwNki3PVgh|ryPNG[1OJdUSU6JRWK=
697NWDYT3kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rQV2lEPTB;Mz62PVYxOyEQvF2=MVzTRW5ITVJ?
HPAF-IIMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXRPJBKSzVyPUOuO|U1QSEQvF2=NXXhNJdOW0GQR1XS
NCI-H2087MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXHNm1uUUN3ME2zMlg1Pjd{IN88US=>NF\PVJNUSU6JRWK=
SK-MEL-3M13MWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTNwOEWxOVQh|ryPM3vIWnNCVkeHUh?=
CGTH-W-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvmSZp1UUN3ME2zMlg2PzJ3IN88US=>NH72OZNUSU6JRWK=
8505CNUTVN3U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3tVo9KSzVyPUOuPVAxPzhizszNMnXvV2FPT0WU
GAMGNXvQ[HFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXiTWM2OD12LkCyN|c4KM7:TR?=MkfJV2FPT0WU
SW626NGXtcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonRTWM2OD12LkC0OFgh|ryPNGfRdXBUSU6JRWK=
CAL-62MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTSWXFDUUN3ME20MlA4PDNizszNMWjTRW5ITVJ?
MHH-PREB-1NWHxfoNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33RTGlEPTB;ND6xNlEyOSEQvF2=MVPTRW5ITVJ?
RPMI-7951NV7DXnVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLKTWM2OD12LkK1OVg6KM7:TR?=M4TobnNCVkeHUh?=
HOP-92MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTRwMkW2O{DPxE1?M2X1d3NCVkeHUh?=
MDA-MB-231NWjmZ|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTRwMkmyNlMh|ryPNH\0PZlUSU6JRWK=
LAN-6NHrlc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{X2SmlEPTB;ND6zNVY{PyEQvF2=NEnvN3hUSU6JRWK=
ALL-POM{jiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\ZN|BKSzVyPUSuN|YyPTZizszNMWLTRW5ITVJ?
HHMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljsTWM2OD12LkSxOVk4KM7:TR?=M2XUZ3NCVkeHUh?=
IGROV-1NVnIO3IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HCRmlEPTB;ND60OVE4OSEQvF2=NGTSbopUSU6JRWK=
NCI-H358NEf0cG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrGTWM2OD12LkS1N|g2KM7:TR?=MU\TRW5ITVJ?
NB5M4DOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTRwNkCzOlkh|ryPM1PxTHNCVkeHUh?=
NCI-H747NWKyZWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYm2SHNZUUN3ME20MlY5QDB5IN88US=>NHfYR|dUSU6JRWK=
NH-12NISxZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTRwN{G2NlUh|ryPMVTTRW5ITVJ?
LB1047-RCCNFjQR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXj3eWFrUUN3ME20Mlc{QDF3IN88US=>NGrHe3JUSU6JRWK=
EFO-27NHjqU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojPTWM2OD12Lke4OlY4KM7:TR?=MnriV2FPT0WU
EPLC-272HM4TiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrHVJBmUUN3ME20Mlk6PjZ7IN88US=>NF;uZ4NUSU6JRWK=
CAL-54MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3mXWJWUUN3ME21MlAzPjl3IN88US=>MVXTRW5ITVJ?
H4M4m2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XofmlEPTB;NT6wOFI2PSEQvF2=NEfMTndUSU6JRWK=
MOLT-13MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXseVJkUUN3ME21MlA3Pzd4IN88US=>M4fiNXNCVkeHUh?=
CAL-33M2HhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXjVXhKSzVyPUWuNVI{OTdizszNMlTHV2FPT0WU
23132-87NIrKdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3yOFdKSzVyPUWuNVY5PzJizszNNGDIVXJUSU6JRWK=
UM-UC-3MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTVwMUiwOFch|ryPM3PqOXNCVkeHUh?=
HuH-7NFr6[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHYZ|NKUUN3ME21MlI4OTR5IN88US=>NGr4SmJUSU6JRWK=
BCPAPMlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LkeGlEPTB;NT6zNlk3QSEQvF2=NIHyWllUSU6JRWK=
AsPC-1NGn2bHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\xc4hkUUN3ME21MlM3PzZ|IN88US=>NHPEU4ZUSU6JRWK=
NCI-H1155NI\OV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXX3[nd7UUN3ME21MlQxODVzIN88US=>MWnTRW5ITVJ?
GT3TKBMlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\RTWM2OD13LkS2OVk5KM7:TR?=Mo\jV2FPT0WU
HCC2998MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTVwNEmxNFkh|ryPM{XP[3NCVkeHUh?=
NUGC-3MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTVwNEmzNFIh|ryPMkLmV2FPT0WU
Hs-578-TNVrX[oloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTVwNUO3PVQh|ryPM{PtdHNCVkeHUh?=
FADUNX[2V2FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NESwPZFKSzVyPUWuOVU4OjZizszNNI\4NHZUSU6JRWK=
NBsusSRNH:xO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIL6eYFKSzVyPUWuOVcyPTVizszNM3;SVXNCVkeHUh?=
ME-180MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTVwNUiwPVIh|ryPM3zae3NCVkeHUh?=
SW1710M4H2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XR[mlEPTB;NT62NVY2PCEQvF2=MnHHV2FPT0WU
HuP-T3M2TwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3oTWM2OD13Lk[yNFI6KM7:TR?=NH73Z5pUSU6JRWK=
HOSM3XiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rBW2lEPTB;NT62NlkzOyEQvF2=M2m3eXNCVkeHUh?=
PA-1NGfMRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTVwNkSyOlUh|ryPNFrEW|ZUSU6JRWK=
LU-99AMl\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPnRXlvUUN3ME21MlY3PDVzIN88US=>Ml7xV2FPT0WU
RS4-11MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTVwNk[3O|Uh|ryPNEDnOFZUSU6JRWK=
TE-8NY\ZUIVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjWZ5NKSzVyPUWuOlg2OzdizszNNVTtOJc{W0GQR1XS
RERF-LC-MSM3;4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHBTWM2OD13Lk[4PFA{KM7:TR?=Mm\kV2FPT0WU
MEL-JUSOMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIezb3hKSzVyPUWuO|M4QCEQvF2=MVHTRW5ITVJ?
SK-MES-1Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoD3TWM2OD13LkizOVI5KM7:TR?=M{fod3NCVkeHUh?=
D-263MGNUflVZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HxO2lEPTB;NT64PFM2OSEQvF2=Ml61V2FPT0WU
NB10M3y5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTVwOEm0OkDPxE1?MVXTRW5ITVJ?
SK-HEP-1M2nvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXa[INKSzVyPUWuPVM1PzFizszNNV3CWWsxW0GQR1XS
HT-29NHnJVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoG2TWM2OD13Lkm4NVE5KM7:TR?=MWHTRW5ITVJ?
KYSE-140Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\TTWM2OD14LkCyNVgzKM7:TR?=NHnMemVUSU6JRWK=
NCI-H1666Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nmS2lEPTB;Nj6wPFQ3OSEQvF2=MYnTRW5ITVJ?
NCI-H1304NVXib|RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXXTWM2OD14LkG5PVQh|ryPM1fmVnNCVkeHUh?=
RPMI-8866MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYW5VIN2UUN3ME22MlIyOzF|IN88US=>MnTqV2FPT0WU
MV-4-11NFjD[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zTbGlEPTB;Nj6yN|E6QSEQvF2=MUHTRW5ITVJ?
A431NUPubHlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYWyW2ZZUUN3ME22MlI1Ojl4IN88US=>MUHTRW5ITVJ?
PANC-10-05NFLlOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;wOogzUUN3ME22MlI5OzZ|IN88US=>MlztV2FPT0WU
TK10MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfZfJdKSzVyPU[uN|I3ODRizszNMUnTRW5ITVJ?
NCI-H1975NVXWWIVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPJTYxKSzVyPU[uOFczOTVizszNMYTTRW5ITVJ?
A172NHLMVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnWSVFKSzVyPU[uOFkyPzZizszNNWnUXGZmW0GQR1XS
D-566MGM3PWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\qe2NKSzVyPU[uOVQ{ODNizszNNX;m[Fl5W0GQR1XS
NCI-H2122MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTZwNkG1Nlgh|ryPM1zpTnNCVkeHUh?=
COR-L105M{HFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3P[YhTUUN3ME22MlY2Ojd3IN88US=>MXHTRW5ITVJ?
AN3-CAMoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfINGQyUUN3ME22MlY5PjRzIN88US=>MX7TRW5ITVJ?
Calu-6NFvYR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jBOWlEPTB;Nj63PVY6QCEQvF2=NUHQb2NtW0GQR1XS
HCT-116NX\LelRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTZwOEGyOlQh|ryPMU\TRW5ITVJ?
MHH-NB-11Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTZwOEWwNFIh|ryPMUDTRW5ITVJ?
MFE-280NEP2dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInQUlFKSzVyPU[uPFU6QDNizszNNEjBSFBUSU6JRWK=
SW1088M1fJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1m4XGlEPTB;Nj65NVkyOyEQvF2=MkDnV2FPT0WU
SW48NIjvbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTkTWM2OD14Lkm0OVEh|ryPNHHUWplUSU6JRWK=
HuCCT1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFr3U5hKSzVyPUeuNFExOzdizszNNETrWnNUSU6JRWK=
ACHNNXTNVZZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfFTIZMUUN3ME23MlAzQTR|IN88US=>NXm5b41{W0GQR1XS
8305CNV:zWWh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTdwMEm5PVUh|ryPMVHTRW5ITVJ?
DoTc2-4510M3vDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHq1NFZKSzVyPUeuNVIyPSEQvF2=NHm2PVhUSU6JRWK=
COR-L23MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvxS2pmUUN3ME23MlI1PDJizszNMYTTRW5ITVJ?
SK-MEL-30MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrkTWM2OD15LkK1NFg{KM7:TR?=M3zsT3NCVkeHUh?=
BE-13M4K2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7jSohKSzVyPUeuN|M5OzRizszNNWHyRYhtW0GQR1XS
GR-STNIC1Z3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;iVFhKSzVyPUeuOFAyPzRizszNMVnTRW5ITVJ?
LU-135MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTdwNUW5N|kh|ryPNV;PUYE5W0GQR1XS
U-266MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILk[3BKSzVyPUeuOVYzQDZizszNM2XqTXNCVkeHUh?=
NCI-H1355NVfXT5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoO3TWM2OD15LkW4OlM2KM7:TR?=MmC0V2FPT0WU
NB14NX3EW5VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XoWGlEPTB;Nz62OlY1OiEQvF2=NHzBdGxUSU6JRWK=
SCC-25NFTQXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTxTWM2OD15LkewPUDPxE1?NFTafJpUSU6JRWK=
COLO-678NVXPO45QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3H3[GlEPTB;Nz63NVA4PiEQvF2=NXrOVlRuW0GQR1XS
TGBC1TKBM4jhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLUTJBCUUN3ME23Mlg6Ozl6IN88US=>NG\ncpZUSU6JRWK=
IST-MEL1NYP5OINMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4mxN2lEPTB;OD6wNFQxPiEQvF2=MoSxV2FPT0WU
ECC10M2T4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRThwMEOzPVUh|ryPNI\yb5ZUSU6JRWK=
EW-16MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nGWWlEPTB;OD6wPFQ1PSEQvF2=Mn23V2FPT0WU
DOHH-2NGe5dYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XhNGlEPTB;OD6yNFA6PSEQvF2=M1K0TnNCVkeHUh?=
NCI-H1581M3PNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETFNpJKSzVyPUiuNlY{OjNizszNM{DUTnNCVkeHUh?=
TE-5NFi2SGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nYTmlEPTB;OD60NlQzQSEQvF2=NVPmcXlWW0GQR1XS
CAKI-1NXXUXVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnz3TWM2OD16LkW3NlIzKM7:TR?=NHXa[ZRUSU6JRWK=
A673NXz4eXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETjUJBKSzVyPUiuOlMzODJizszNNEHSPFJUSU6JRWK=
CAL-12TMoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TlT2lEPTB;OD62OVc2OyEQvF2=M1rTc3NCVkeHUh?=
DBTRG-05MGMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17PUmlEPTB;OD63OFg2QSEQvF2=MWfTRW5ITVJ?
SK-N-FIMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TDRWlEPTB;OD64NVM4QSEQvF2=M4fRdXNCVkeHUh?=
K-562M1ewZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG[ycolKSzVyPUiuPFM6PTdizszNM2HXeXNCVkeHUh?=
SBC-1M4KwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRThwOE[2OFUh|ryPMni3V2FPT0WU
ES4MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlW5TWM2OD16Lki2PFg1KM7:TR?=MUDTRW5ITVJ?
MS-1NXTDeWlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXpTWM2OD16Lki3OVE4KM7:TR?=NV\mWWt4W0GQR1XS
RKOMk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXVeVNKSzVyPUiuPFkxPTdizszNMnXiV2FPT0WU
NCI-H1693MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjFSFRDUUN3ME24MlkzOTdizszNNVvZVGZpW0GQR1XS
SW954M2q3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRThwOU[5O|gh|ryPNXniWFVHW0GQR1XS
SK-UT-1NX7uUIxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUP3ZZRrUUN3ME24Mlk4Pjh|IN88US=>NInOU4ZUSU6JRWK=
T98GNFP3NWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fOWWlEPTB;OD65PVg1PiEQvF2=MYPTRW5ITVJ?
NCI-H2126MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DXbWlEPTB;OT6wNFgzPiEQvF2=MmX6V2FPT0WU
TE-12Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPaTWM2OD17LkCzN|Y4KM7:TR?=MV\TRW5ITVJ?
DK-MGMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TOfGlEPTB;OT6yNVE6OSEQvF2=M2X3O3NCVkeHUh?=
MEG-01NYm1WolNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;qdI9KSzVyPUmuNlQ6OzFizszNNVHxc3hsW0GQR1XS
HCC1937MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzaTWM2OD17LkK5NFkyKM7:TR?=Mmm0V2FPT0WU
MKN45NFvHRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPFVnl7UUN3ME25MlQ2ODZ3IN88US=>NH;6SWhUSU6JRWK=
NCI-H1792MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmruTWM2OD17LkS1NlE6KM7:TR?=MWjTRW5ITVJ?
SW1417M{PuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3X4S2lEPTB;OT61Olg{PyEQvF2=MnH3V2FPT0WU
639-VMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTlwNkSzPFgh|ryPM{nOdXNCVkeHUh?=
P30-OHKM{DxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnKTpp3UUN3ME25MlY2OzF4IN88US=>NV3kXo9nW0GQR1XS
YKG-1Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\LRmlEPTB;OT63OVA{OyEQvF2=M2HzOnNCVkeHUh?=
KGNMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTlwOEO3PVUh|ryPNXuyT5I{W0GQR1XS
MSTO-211HMmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjNPXhKSzVyPUmuPVU2OjlizszNM3XUOHNCVkeHUh?=
NCI-H1573M4j6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTFyLkG1O|Qh|ryPNF3me2tUSU6JRWK=
NCI-H720MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTFyLkG5PFkh|ryPMVHTRW5ITVJ?
KARPAS-45M{PjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2X4UWlEPTB;MUCuNlc6PSEQvF2=Mk\iV2FPT0WU
MDA-MB-175-VIIMn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTqTWM2OD1zMD60PEDPxE1?M3L0fXNCVkeHUh?=
SK-NEP-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\uVYxHUUN3ME2xNE41QThzIN88US=>M2nqcHNCVkeHUh?=
MKN28MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTFyLkWxPEDPxE1?MnnyV2FPT0WU
KYSE-520NYfQOo5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2WzPWlEPTB;MUCuOVIh|ryPMne1V2FPT0WU
KE-37MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEX4VoJKSzVyPUGwMlUzPzJizszNNHzFXIVUSU6JRWK=
VA-ES-BJMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHt[ol{UUN3ME2xNE42PjdizszNMWLTRW5ITVJ?
CCRF-CEMM3fqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\3c2lsUUN3ME2xNE42Pjh2IN88US=>NIHWUGJUSU6JRWK=
GMS-10NHX4UW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWm4[YdCUUN3ME2xNE43ODl2IN88US=>M2DUTnNCVkeHUh?=
NCI-H1623M4PMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\VTWM2OD1zMD62N|c6KM7:TR?=NEL1SWZUSU6JRWK=
NEC8Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGWyfJdKSzVyPUGwMlc4PzNizszNMoHaV2FPT0WU
MOLT-16M1;kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XFcWlEPTB;MUCuPFEyOyEQvF2=M1XLSXNCVkeHUh?=
DJM-1NVPoVGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIC2W4JKSzVyPUGxMlA{PzlizszNNV3NbnJ2W0GQR1XS
U251M3jwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTSWpFKSzVyPUGxMlA1OiEQvF2=MVfTRW5ITVJ?
SBC-5M{LQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\qXpRQUUN3ME2xNU4yPDZ5IN88US=>MkXtV2FPT0WU
SW756NXnYe2VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTlRmZFUUN3ME2xNU4zOTV2IN88US=>MnTMV2FPT0WU
KS-1NU\N[pd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\kVGlEPTB;MUGuNlYyQSEQvF2=NILlU3FUSU6JRWK=
SF295MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;FTWM2OD1zMT6zNVA1KM7:TR?=MWnTRW5ITVJ?
YH-13MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlz2TWM2OD1zMT6zNlY4KM7:TR?=MVXTRW5ITVJ?
SW837NHSwSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{e1eWlEPTB;MUGuN|UxPiEQvF2=M3TKUHNCVkeHUh?=
KYSE-450NV3ISG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVqwfoVsUUN3ME2xNU41ODV5IN88US=>M3XVXXNCVkeHUh?=
KYSE-180MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fqUGlEPTB;MUGuOFgzKM7:TR?=MlWxV2FPT0WU
S-117NH3LRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\vOGlEPTB;MUGuOFg6PiEQvF2=MYXTRW5ITVJ?
KOSC-2MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmj2TWM2OD1zMT62NlIzKM7:TR?=MWHTRW5ITVJ?
KYSE-270NEnWPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrpbIlNUUN3ME2xNU45PzR3IN88US=>MXnTRW5ITVJ?
D-336MGMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPzTWM2OD1zMT65NFc2KM7:TR?=MoP5V2FPT0WU
KALS-1M3TWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHMTWM2OD1zMj6wNFE3KM7:TR?=M4O2bXNCVkeHUh?=
LB373-MEL-DNUPEVZNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvGfXBKSzVyPUGyMlA2OzNizszNNV60SFZJW0GQR1XS
HLEM{naPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWG3OmoxUUN3ME2xNk4xPTh3IN88US=>Mor3V2FPT0WU
SJSA-1MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XnT2lEPTB;MUKuNFc{PSEQvF2=NYDJUohuW0GQR1XS
SW1990MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTF{LkC5NVEh|ryPM2WwWnNCVkeHUh?=
NOS-1M1n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULQNG5FUUN3ME2xNk4yOzV{IN88US=>MV\TRW5ITVJ?
GI-ME-NMnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPaNoZsUUN3ME2xNk4zOTZ|IN88US=>NVrGcGp[W0GQR1XS
NCI-H1703NIjqOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoixTWM2OD1zMj6yOlE3KM7:TR?=MoXzV2FPT0WU
ES7Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULrWmhsUUN3ME2xNk4zPzJ2IN88US=>M2nrOHNCVkeHUh?=
KYSE-510M37ZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Moe4TWM2OD1zMj61NFc6KM7:TR?=M{C4S3NCVkeHUh?=
BHYMmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTF{LkWzNFch|ryPNV7EU|BTW0GQR1XS
TCCSUPMnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDqTWM2OD1zMj61O|U4KM7:TR?=MlHyV2FPT0WU
HSC-2MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXT4c2JpUUN3ME2xNk42QTl4IN88US=>MlfnV2FPT0WU
BENMofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXocFV7UUN3ME2xNk43OTR|IN88US=>MVrTRW5ITVJ?
769-PMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTF{Lke5NlQh|ryPM{LjcHNCVkeHUh?=
HTM{nIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTF{LkizOFYh|ryPM1\hSnNCVkeHUh?=
LXF-289NGHQemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3scFNKSzVyPUGyMlk2OzFizszNNUfjdlQ6W0GQR1XS
OVCAR-3NHrSN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnhTWM2OD1zMj65OVY4KM7:TR?=NFnXdGJUSU6JRWK=
ATN-1NIrpSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;PZmlEPTB;MUOuNFE5PCEQvF2=NEj0dJJUSU6JRWK=
8-MG-BAMkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlG4TWM2OD1zMz6wOFU2KM7:TR?=Mni2V2FPT0WU
SW13NFu5O|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYqyfHBpUUN3ME2xN{4yOTZ3IN88US=>MYfTRW5ITVJ?
NCI-H1092M4fXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jwd2lEPTB;MUOuNVYzKM7:TR?=NUC1R2xqW0GQR1XS
OAW-42NFrBO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\qTWM2OD1zMz6xPVM4KM7:TR?=MVrTRW5ITVJ?
NCI-H2452M1;NV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\nTWM2OD1zMz6yNVc2KM7:TR?=NEj3[XZUSU6JRWK=
CAPAN-1M1OwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDQeWhGUUN3ME2xN{42PTF2IN88US=>NEDEbZdUSU6JRWK=
NCI-H2009Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnrOG9KSzVyPUGzMlU6OTlizszNNUH0ZnpoW0GQR1XS
SF268NILsVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3Ub4FKSzVyPUGzMlY{OjZizszNM2XRWnNCVkeHUh?=
GCIYNIfoPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTF|Lk[5Nlch|ryPMYXTRW5ITVJ?
OS-RC-2MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nYfmlEPTB;MUOuPVUxOSEQvF2=NFfncG1USU6JRWK=
GCTNVTCWINST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7ZTWM2OD1zMz65Olk4KM7:TR?=M2XyXXNCVkeHUh?=
NB17NWjXWnRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHL4NYhKSzVyPUG0MlA5PSEQvF2=MX7TRW5ITVJ?
NCI-H2030Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTF2LkG0OlUh|ryPM13BZnNCVkeHUh?=
HC-1M2q5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTF2LkKwPFch|ryPNWHW[ZVYW0GQR1XS
QIMR-WILNWnZUGZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXEUY5RUUN3ME2xOE4{PDF{IN88US=>NGjUV|lUSU6JRWK=
Capan-2MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXruZZNUUUN3ME2xOE4{PzF2IN88US=>NFm4Z5pUSU6JRWK=
BALL-1MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHr0PFdKSzVyPUG0MlQ3PjVizszNMoLMV2FPT0WU
LS-1034MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXufIdKSzVyPUG0MlYyPTJizszNNIrVTWtUSU6JRWK=
U-118-MGMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\4[HpKSzVyPUG0MlY{OSEQvF2=M2rwRnNCVkeHUh?=
NCI-H630NH7WO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTF2Lk[1Olgh|ryPM1LpZnNCVkeHUh?=
OVCAR-8M1WwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHzT5p[UUN3ME2xOE44OjBzIN88US=>NXXCelViW0GQR1XS
NCI-H2347MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rUOGlEPTB;MUSuPFI{KM7:TR?=M37RT3NCVkeHUh?=
BT-549NVyzcW9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrRTWM2OD1zND64Nlg1KM7:TR?=M2Xae3NCVkeHUh?=
LB831-BLCMnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DRSGlEPTB;MUSuPFk{PCEQvF2=NYfKfGtoW0GQR1XS
NCI-H661M2frSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XG[WlEPTB;MUSuPVU6KM7:TR?=NIPYdVZUSU6JRWK=
MKN7MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITi[ZBKSzVyPUG1MlAxQTNizszNMkLOV2FPT0WU
U-87-MGNUXlc5BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnU[o0zUUN3ME2xOU4xQDl5IN88US=>NULh[FkxW0GQR1XS
OVCAR-4M4X4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTF3LkG0NlQh|ryPMYXTRW5ITVJ?
OE33Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fEVGlEPTB;MUWuNVcyOSEQvF2=NEfU[IlUSU6JRWK=
EC-GI-10NHjVV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTFNmRKSzVyPUG1MlI{PTdizszNNFLkWoZUSU6JRWK=
AM-38MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml25TWM2OD1zNT6yO|E4KM7:TR?=NUCwPJFWW0GQR1XS
NCI-H1563MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTF3LkO0PUDPxE1?Ml7iV2FPT0WU
SCC-4MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjwZ2VCUUN3ME2xOU41OTB|IN88US=>M2\5NHNCVkeHUh?=
Detroit562NELYPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDHVFVKSzVyPUG1MlQ2PDdizszNNG\O[YJUSU6JRWK=
PC-14M4m4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljrTWM2OD1zNT60PFY3KM7:TR?=NIfBVphUSU6JRWK=
ES3NVnaeG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTF3LkWzOkDPxE1?NWPrVpdUW0GQR1XS
OCI-AML2MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HET2lEPTB;MUWuO|YyPCEQvF2=MVjTRW5ITVJ?
LU-134-AM1vJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\GTWM2OD1zNT65NFE5KM7:TR?=NXW3eWRMW0GQR1XS
SASMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkixTWM2OD1zNT65N|c{KM7:TR?=M4L0c3NCVkeHUh?=
TGBC11TKBMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HocWlEPTB;MUWuPVQyPCEQvF2=MYDTRW5ITVJ?
HOP-62M2fqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2SxU2lEPTB;MUWuPVU6PyEQvF2=MmHSV2FPT0WU
G-401MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;WfWlEPTB;MUWuPVY1QSEQvF2=NHXGeWRUSU6JRWK=
NCI-H28NEKwWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\B[2lEPTB;MU[uNFg2PiEQvF2=MV3TRW5ITVJ?
A204MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWixeopkUUN3ME2xOk4zODB4IN88US=>NGPoRWtUSU6JRWK=
NCI-H1299NUC4SnNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjRbm8{UUN3ME2xOk4zOjlzIN88US=>MYjTRW5ITVJ?
VMRC-RCZM{nZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXUcpN3UUN3ME2xOk4zPTl{IN88US=>MlfmV2FPT0WU
BxPC-3MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1T3VGlEPTB;MU[uNlg2PiEQvF2=NWH5fVBXW0GQR1XS
NCI-H2228M4XCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTmTWM2OD1zNj61NVU5KM7:TR?=NI\2e5FUSU6JRWK=
NCI-H23NXiySGhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\JRmlEPTB;MU[uOlA4QCEQvF2=NVzJdVByW0GQR1XS
NKM-1MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PSTWlEPTB;MUeuNFE5QSEQvF2=NIO1XnlUSU6JRWK=
KYSE-70MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTF5LkK4PUDPxE1?MYHTRW5ITVJ?
BB49-HNCMkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIraXoRKSzVyPUG3MlU3QDZizszNM2HKTHNCVkeHUh?=
SCC-15M2H3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LaNGlEPTB;MUeuPFQ4OyEQvF2=MXPTRW5ITVJ?
D-247MGNXrjdWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGH6WmlKSzVyPUG3MlkzPDdizszNM2\MWnNCVkeHUh?=
BB30-HNCM2PUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;aXIR2UUN3ME2xPE4xOzF6IN88US=>NGT1dW9USU6JRWK=
CAL-85-1MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXlUmt2UUN3ME2xPE4yQDB7IN88US=>NF;xSndUSU6JRWK=
HT-3NUXrXIZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nDXmlEPTB;MUiuN|k4PyEQvF2=M4OzT3NCVkeHUh?=
KYSE-410NXXkTXVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrPWWdPUUN3ME2xPE41PTd5IN88US=>NVXiclJyW0GQR1XS
SW982MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTF6LkW2OFkh|ryPMkLTV2FPT0WU
SW962MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDTTWM2OD1zOD61O|AzKM7:TR?=NWHxXmVNW0GQR1XS
Ramos-2G6-4C10M2nDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3sV25PUUN3ME2xPE42QTJ5IN88US=>MVPTRW5ITVJ?
OC-314MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLkR3ZpUUN3ME2xPE44Ozh2IN88US=>M{fMXnNCVkeHUh?=
LS-123NFzqZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojWTWM2OD1zOD63PVAyKM7:TR?=MYHTRW5ITVJ?
D-502MGMnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnrPFhKSzVyPUG4MlgyOzlizszNM1jpcHNCVkeHUh?=
RO82-W-1M3;MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LtRWlEPTB;MUiuPFI5QCEQvF2=M3;u[nNCVkeHUh?=
HuO9MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTF7LkGzO|kh|ryPM4DSSnNCVkeHUh?=
ETK-1Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjCUJRKSzVyPUG5MlE5OjdizszNNX7OToFGW0GQR1XS
SNU-387MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TXVGlEPTB;MUmuNVg5QSEQvF2=M323UXNCVkeHUh?=
SW1573MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXr6c|FVUUN3ME2xPU4yQTZ7IN88US=>MlvYV2FPT0WU
NTERA-S-cl-D1M4\tRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILMUmRKSzVyPUG5MlIxODdizszNMYnTRW5ITVJ?
SF126MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYm0PINxUUN3ME2xPU4{PTB{IN88US=>M{jWcnNCVkeHUh?=
Calu-3NFPhTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nyNWlEPTB;MUmuOFI{PyEQvF2=MWrTRW5ITVJ?
NCI-H1048NIPiXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXy5W3pRUUN3ME2yNE4{OjZ4IN88US=>NYLF[ZF7W0GQR1XS
NCI-H226MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXWeZJKSzVyPUKwMlQ{QTlizszNMljpV2FPT0WU
FTC-133MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3P1OWlEPTB;MkCuOFcxOyEQvF2=NGLM[|JUSU6JRWK=
SF539NGPZSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHToW2pKSzVyPUKwMlUyPzJizszNM1jHW3NCVkeHUh?=
TE-6M2H0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjWVpRKSzVyPUKwMlgxPjdizszNNWnNWHdnW0GQR1XS
UMC-11MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTJyLkmxOlQh|ryPM3G1XnNCVkeHUh?=
BeckerMmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPU[lRjUUN3ME2yNU4yOTF6IN88US=>NVLKU5ZEW0GQR1XS
KP-4MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4T3cmlEPTB;MkGuNVE6PiEQvF2=M2rCfXNCVkeHUh?=
ChaGo-K-1M{TJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHPTWM2OD1{MT6zOlI4KM7:TR?=MW\TRW5ITVJ?
CFPAC-1MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTJzLkO4OVgh|ryPNVrzfJR2W0GQR1XS
A498M{XLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHr2SI9KSzVyPUKxMlU{OTJizszNNHzwSWZUSU6JRWK=
NCI-H1755NHvrN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmX4TWM2OD1{MT62O|QyKM7:TR?=MVzTRW5ITVJ?
TI-73NH;Sc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLITWM2OD1{Mj6zNlgh|ryPNYf5Z|VOW0GQR1XS
NCI-H441NIrnT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTJ{LkW2PFkh|ryPMWHTRW5ITVJ?
CaR-1M37qOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTJ|LkCyNVMh|ryPNGKzS|lUSU6JRWK=
HCC1806MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILKdGtKSzVyPUKzMlA2QDNizszNNH;VSYhUSU6JRWK=
SNU-449MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYewflR2UUN3ME2yN{4{OjlizszNNUnx[|VQW0GQR1XS
EKVXNUOxXmhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUD0dFdwUUN3ME2yN{4{QTB7IN88US=>Mle1V2FPT0WU
DMS-114M2P6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7VTWM2OD1{Mz61O|Y2KM7:TR?=NI\2Z2VUSU6JRWK=
A704MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4P1S2lEPTB;MkOuOlExOyEQvF2=MYDTRW5ITVJ?
LC-2-adMkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTJ|Lk[xOFch|ryPNI\lc|BUSU6JRWK=
VM-CUB-1NVHwR5M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrJTWM2OD1{Mz63N|QyKM7:TR?=MYXTRW5ITVJ?
PC-3M3zjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXWbFFKSzVyPUK0MlA2OjZizszNMXzTRW5ITVJ?
HELM3zWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVn6dJBDUUN3ME2yOE4xQDZ3IN88US=>M3PJbXNCVkeHUh?=
ABC-1NWLRR292T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJ2LkK3Nlkh|ryPMXzTRW5ITVJ?
COLO-680NNXfCdWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTlUVhEUUN3ME2yOE41PzZ2IN88US=>NF\UNmNUSU6JRWK=
MZ1-PCMoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzWRXFuUUN3ME2yOE43QDdizszNMVPTRW5ITVJ?
NCI-H69NFXrVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTJ2LkezOVQh|ryPNUPESmZMW0GQR1XS
TE-1NULrU2JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXmzbGl[UUN3ME2yOU4xPDl7IN88US=>NYXYT2w{W0GQR1XS
EW-3NYnveWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nrS2lEPTB;MkWuNVE{KM7:TR?=MYTTRW5ITVJ?
PANC-08-13MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXqdZR[UUN3ME2yOU45OTB|IN88US=>M3jXPXNCVkeHUh?=
NMC-G1NXvQbG13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHYN5RZUUN3ME2yOk4xODh6IN88US=>M1rMNHNCVkeHUh?=
BT-20MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlziTWM2OD1{Nj60OVQ{KM7:TR?=Mn[4V2FPT0WU
TGBC24TKBNI\YZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGS4cnFKSzVyPUK2Mlc{OzFizszNNX3OO5ZlW0GQR1XS
TE-11MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XXcmlEPTB;Mk[uPVg6PSEQvF2=MV\TRW5ITVJ?
ESS-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTJ5LkOyNVYh|ryPMVvTRW5ITVJ?
JVM-3MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;ZS2lEPTB;MkeuOlQ4PSEQvF2=NXPqUHlUW0GQR1XS
C3ANEjvOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnOWYQ2UUN3ME2yO{45PDl4IN88US=>Mo[wV2FPT0WU
MDA-MB-157MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTQRmpKSzVyPUK3Mlg4PTNizszNMWnTRW5ITVJ?
KLENF3RVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJ6LkGwOVgh|ryPNHzXcFdUSU6JRWK=
ES1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUeyO2doUUN3ME2yPE4yQDN6IN88US=>Ml\MV2FPT0WU
CAL-120M2jkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTJ6LkO5PVkh|ryPM4TGSnNCVkeHUh?=
NCI-N87NYnh[YpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLWTWM2OD1{OD61NVA2KM7:TR?=MlPPV2FPT0WU
RPMI-8226MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGm1W4tKSzVyPUK5MlE5PDNizszNNH:0bJpUSU6JRWK=
COR-L88NVTmcYtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPkTWM2OD1{OT6yOFE6KM7:TR?=NXftOpp[W0GQR1XS
UACC-893MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTJ7LkOxN|ch|ryPMVrTRW5ITVJ?
C8166NWTEd2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTJ7Lkm5PVYh|ryPMVXTRW5ITVJ?
J82NU\KTmF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTNyLkixOFch|ryPNHjJbIRUSU6JRWK=
PFSK-1NV71NXB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XIcmlEPTB;M{GuNFY2QSEQvF2=MlnnV2FPT0WU
COLO-684NHLKR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPrTWM2OD1|MT60N|c1KM7:TR?=MWHTRW5ITVJ?
CAL-72MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTtNIdlUUN3ME2zNU42PzJ7IN88US=>M3fqcHNCVkeHUh?=
SNB75NXXMSVFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHsTWM2OD1|MT64PVch|ryPMkn1V2FPT0WU
MDA-MB-415MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTvTWM2OD1|MT65O|YzKM7:TR?=M1zWVXNCVkeHUh?=
SiHaMn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LXUGlEPTB;M{KuOFcyOSEQvF2=NYPWeIhtW0GQR1XS
NCI-H1648MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{P5N2lEPTB;M{KuPVM1PSEQvF2=M4DsVXNCVkeHUh?=
EFO-21NU\xdG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\sNJFCUUN3ME2zN{4xODVizszNMlzrV2FPT0WU
HCC38M1\wVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvj[WlNUUN3ME2zN{4{QDRzIN88US=>Mn;qV2FPT0WU
IA-LMNWHzZpNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTN|Lke4PFkh|ryPM{TBWHNCVkeHUh?=
CTV-1NUHZUm5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjp[4pJUUN3ME2zN{46Pzh4IN88US=>MXrTRW5ITVJ?
NCI-H446MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTN2LkK2PFkh|ryPMULTRW5ITVJ?
IST-SL1NWfqN5pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVmzdnY6UUN3ME2zOE44PDB6IN88US=>M4D4fHNCVkeHUh?=
EW-22NWn1N|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTN2Lke3OVkh|ryPMXnTRW5ITVJ?
JEG-3MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrucZZZUUN3ME2zOk4yPzZ4IN88US=>NVu0UmtrW0GQR1XS
LU-65Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XlNGlEPTB;M{[uNlk5PSEQvF2=NX7xcYdmW0GQR1XS
NCI-H596NV72Z|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETVdY1KSzVyPUO2Mlk2QTFizszNNYDp[GZFW0GQR1XS
KNS-81-FDM{LydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvDTWM2OD1|Nz6xOFUh|ryPMo\4V2FPT0WU
NCI-H1793NWfVO|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTN5LkewPFYh|ryPM3HqbnNCVkeHUh?=
NCI-H460M3zPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DzWGlEPTB;M{iuNFg4OyEQvF2=MoHjV2FPT0WU
MPP-89M{LoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLUdGdpUUN3ME2zPU42QDh4IN88US=>M3TWPXNCVkeHUh?=
D-542MGMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrXT3FKSzVyPUO5Mlg1OzZizszNNXnaOWduW0GQR1XS
JARMlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7qRYl6UUN3ME20NE41PzB3IN88US=>NYrqZZNrW0GQR1XS
NCI-H209MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1naNmlEPTB;NECuOlc4KM7:TR?=NYnyNIdGW0GQR1XS
G-402M4C1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrRTWM2OD12MT6zPVk{KM7:TR?=NXTMeZVmW0GQR1XS
IST-MES1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnUepZ6UUN3ME20Nk4yQTN3IN88US=>M{[0OHNCVkeHUh?=
DaoyMm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDxTWM2OD12Mj61OFcyKM7:TR?=M3\qOnNCVkeHUh?=
EW-11MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTR|LkGyNVEh|ryPNHvWelVUSU6JRWK=
Saos-2NUHvXoNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTR|LkG1N|ch|ryPNWLyVFVDW0GQR1XS
no-10MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\yfWlEPTB;NEOuNVcxOiEQvF2=NXvYXXBsW0GQR1XS
HCC1395M2rucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTR|LkS2OFQh|ryPM3\nenNCVkeHUh?=
HCE-4NEPiUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPsfVFwUUN3ME20N{44PjZ2IN88US=>Mni4V2FPT0WU
EW-1Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{L3Z2lEPTB;NEOuPFA1QSEQvF2=MYnTRW5ITVJ?
OCUB-MMn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfLTWM2OD12ND6zOlM5KM7:TR?=MlzqV2FPT0WU
IGR-1MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfjcpNWUUN3ME20OE41OTF3IN88US=>MlnSV2FPT0WU
NCI-H1838M3\RZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLWTWM2OD12ND60N|Q6KM7:TR?=Ml3nV2FPT0WU
NCI-H2405NXjsdJNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTR2LkWzOEDPxE1?M3\rNHNCVkeHUh?=
GB-1M2fFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV32RphjUUN3ME20OE44PDZ|IN88US=>NFrvXIRUSU6JRWK=
MG-63M3;6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1G1[WlEPTB;NE[uNFY6PiEQvF2=NUnzXIQ3W0GQR1XS
KP-N-YNM2n5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHKPIZKSzVyPUS2MlQ3PzlizszNNVGw[ppSW0GQR1XS
no-11M4G1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHSXWRXUUN3ME20O{4xOjR2IN88US=>NXLFWZE4W0GQR1XS
SW948NW\2[o1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTR5LkOzO|ch|ryPNEfibo9USU6JRWK=
CAMA-1NIT0TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTR5LkO0N|gh|ryPMki3V2FPT0WU
HCC1187NXLaNpo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHX5Zo1KSzVyPUS3MlUyKM7:TR?=NWe3[5RpW0GQR1XS
D-392MGMon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTR5Lk[1NVYh|ryPNVzuPXczW0GQR1XS
647-VNFjWUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTR7LkO0NVQh|ryPNGPiVYZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]
Features First MEK inhibitor to begin clinical development.

Protocol(Only for Reference)

Kinase Assay:

[2]

MEK1 Assay MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.

Cell Assay:

[1]

Cell lines Colon 26 carcinoma cells
Concentrations 0.1-10 μM
Incubation Time 24 hours
Method

Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.

Animal Study:

[3]

Animal Models PTC cells in athymic mice
Formulation Cremophor EL–95% ethanol (50:50) and dilutes with water
Dosages 150 mg/kg
Administration Orally twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Sebolt-Leopold JS, et al. Nat Med, 1999, 5(7), 810-816.

[2] Davies SP, et al. Biochem J, 2000, 135(1), 95-105.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Insti  ...more University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Chemical Information

Download PD184352 (CI-1040) SDF
Molecular Weight (MW) 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, pH 9 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide

Customer Product Validation (12)


Click to enlarge
Rating
Source Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck
Method Immunohistochemistry
Cell Lines Hand2d/d mice
Concentrations
Incubation Time 24h
Results The epithelia of vehicle-treated horn showed prominent expression of p-FRS2 and p-ERK1/2(Fig.A,a and c). However, the levels of both p -FRS2 and p -ERK1/2 were reduced in the epithelia of PD173074-treated horn on day 4 of pregnancy (Fig. A, b and d). We also observed a marked decline in the proliferative activity of Hand2-null uterine epithelia, as indicated by decreased Ki-67 staining (Fig. A, e and f) . In parallel experiments, administration of PD184352, an inhibitor of the ERK1/2 pathway, to uterine horns of Hand2 d/d mice suppressed the level of pERK1/2 (Fig.B, a and b) , as well as luminal epithelial proliferation ( Fig. B, c and d).The ERK1/2-dependent phosphorylation of epithelial ERα at Ser118 is critical for the transcriptional activation of ERα. Administration of either PD173074 (Fig. C, a to d) or PD184352 (Fig. C, e to h) to Hand2-null uterine horns blocked the phosphorylation of epithelial ERα at Ser118 and the expression of Muc -1.

Click to enlarge
Rating
Source J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck
Method Western Blot
Cell Lines primary human melanocytes
Concentrations 1 uM
Incubation Time 18 h
Results In BRAFV600E melanoma cells, the highly selective BRAFV600E inhibitor GDC-0879 and three selective MEK inhibitors [PD184352/CI-1040, U0126, PD98059] did not suppress c-Jun levels, although they effectively reduced phospho-ERK levels.

Click to enlarge
Rating
Source J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck
Method Xenograft
Cell Lines athymic nude Foxn1nu mice
Concentrations 3 mg/kg
Incubation Time 13 day
Results CDK2/4 inhibition augmented statistically significant growth reduction of melanoma xenografts in vivo by the BRAF and MEK inhibitors (GDC-0879 and CI1040).

Click to enlarge
Rating
Source Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck
Method Western blot
Cell Lines DU145/PC3 cells
Concentrations 10 μM
Incubation Time 12 h
Results PI3K inhibition by LY294002 in-creased ERK activation in Her2-overexpressing DU145 cells, whereas treatment with the MEK inhibitor PD184352 in PC3 cells with Her2 overexpression resulted in increased AKT activation. This suggests a strong reciprocal feedback regulation of the PI3K/AKT and MEK/ERK signaling cascades (Fig. E)

Click to enlarge
Rating
Source Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck
Method MTT assay
Cell Lines MDA-MB-453 cell line, HCC-1954 cell line
Concentrations 2-25 μM
Incubation Time 48 h
Results We observed that monotherapies with CI-1040 and other inhibitors reduced cell viability in a dose-dependent manner across these cell lines

Click to enlarge
Rating
Source Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck
Method MTT assay/Western blot
Cell Lines MDA-MB-453-R cell line
Concentrations 5/10 μM
Incubation Time 48 h
Results "Flutamide and CI-1040 treatments were carried out at the same four dose combinations applied before in the nonresistant line (CI-1040(5μM)/flutamide(5μM), CI-1040 (10μM) /flutamide (5μM), CI-1040 (5μM)/flutamide (10μM), and CI-1040(10 μM)/f lutamide (10μM)). Importantly, we observed a synergy at all four dose combinations in MDA -MB-453-R line with CI values of 0.68 to 0.76 (Figure D). Combination therapies with CI-1040 (5μM)/f lutamide (5μM) and CI-1040 (5μM)/flutamide (10μM) completely abrogated ERK phosphorylationin MDA-MB-453-R line (Figure F).

Click to enlarge
Rating
Source Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck
Method Western blot
Cell Lines MDA-MB-453 cell lines, HCC-1954 cell lines
Concentrations 10 μM
Incubation Time 24 h
Results We observed that CI-1040 at 10μM concentration almost completely inhibited ERK phosphorylation in both cell lines

Click to enlarge
Rating
Source Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck
Method RT-PCR
Cell Lines MDA-MB-453 cell lines, HCC-1954 cell lines
Concentrations 10 μM
Incubation Time 24 h
Results We assessed AR expression using RT-PCR and observed a significant reduction of AR transcript level after MEK inhibition by CI-1040 to 0.2- and 0.6-fold in MDA-MB- 453 and HCC-1954 cells, respectively, compared with the controls (P < .01; Figure A). This finding suggest that ERK signaling regulates AR expression in molecular apocrine cells.

Click to enlarge
Rating
Source Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck
Method MTT assay
Cell Lines MDA-MB-453 cell line, HCC-1954 cell line, HCC-202 cell line
Concentrations 5/10 μM
Incubation Time 48 h
Results These data suggest that AR inhibitor flutamide and MEK inhibit or CI-1040 have synergy in reducing cell viability of molecular apocrine cell lines.

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source 2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck
Method Cell colony formation assays
Cell Lines primary hematopoietic cells
Concentrations 10 μM
Incubation Time
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related MEK Products

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • Binimetinib (MEK162, ARRY-162, ARRY-438162)

    Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

  • Refametinib (RDEA119, Bay 86-9766)

    Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Recently Viewed Items

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us